We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Exact Sciences Corp (EXAS) USD0.01

Sell:$52.00 Buy:$54.37 Change: $0.16 (0.30%)
Market closed |  Prices as at close on 22 November 2024 | Switch to live prices |
Sell:$52.00
Buy:$54.37
Change: $0.16 (0.30%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 22 November 2024 | Switch to live prices |
Sell:$52.00
Buy:$54.37
Change: $0.16 (0.30%)
Market closed |  Prices as at close on 22 November 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Company’s products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, and OncoExTra Test. The Company’s flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.

Contact details

Address:
5505 Endeavor Lane
MADISON
53719
United States
Telephone:
+1 (608) 2845700
Website:
https://www.exactsciences.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
EXAS
ISIN:
US30063P1057
Market cap:
$9.75 billion
Shares in issue:
185.08 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Kevin Conroy
    Chairman of the Board, President, Chief Executive Officer
  • Aaron Bloomer
    Chief Financial Officer
  • Brian Baranick
    Executive Vice President, General Manager - Precision Oncology
  • Jacob Orville
    Executive Vice President, General Manager - Screening
  • Sarah Condella
    Executive Vice President - Human Resources
  • Everett Cunningham
    Executive Vice President
  • James Herriott
    Senior Vice President, General Counsel, Company Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.